Nexalin (Nasdaq: NXL) CEO Mark White Highlights Drug-Free Mental Health Platform

In our live investor webinar, Mark White, CEO of Nexalin (Nasdaq: NXL), explains how the company’s proprietary Deep Intracranial Frequency Stimulation (DIFS™) technology is designed to deliver a drug-free, non-invasive 45-minute treatment that is undetectable to the human body. In simple terms, Nexalin is targeting abnormal brain signaling patterns with frequency-based stimulation aimed at helping normalize neuronal activity and related neurohormonal balance.

Watch our live webinar replay to hear Mark White discuss Nexalin’s technology, clinical progress, regulatory roadmap, and long-term growth strategy with investors.

Watch the full replay: https://redchip.news/3NlqbCT

#NXL #Nexalin #Nasdaq #HealthcareStocks #BiotechStocks #MedicalDevices #MentalHealth #Neurostimulation #SmallCapStocks #StockMarket #InvestorWebinar

Видео Nexalin (Nasdaq: NXL) CEO Mark White Highlights Drug-Free Mental Health Platform канала RedChip Companies